The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Active Surveillance for Stage I Seminoma: Avoiding Adjuvant Therapy

Risk-stratified active surveillance approach for clinical stage I seminoma minimizing treatment-related morbidity while preserving cure

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Active Surveillance for Stage I Seminoma: Avoiding Adjuvant Therapy?

Active surveillance avoids adjuvant therapy in clinical stage I seminoma reserving treatment for relapse.

Stage I seminoma represents disease confined to testis without nodal or distant metastases after orchiectomy.

Cure rates with active surveillance approach 100% with appropriate salvage at relapse equaling adjuvant therapy.

Approximately 80-85% of patients avoid any further treatment with active surveillance.

Long-term survivorship benefits include avoidance of secondary malignancy and cardiovascular toxicity from adjuvant therapy.

Symptoms

Stage I seminoma typically presents asymptomatically following orchiectomy for testicular mass.
Relapses during surveillance manifest as enlarging retroperitoneal lymphadenopathy on imaging.
Beta-hCG elevation during surveillance suggests relapse with non-seminomatous component.
Constitutional symptoms including weight loss, fatigue may suggest advanced relapse warranting workup.
Most relapses are detected on routine surveillance imaging in asymptomatic patients.

Risk Factors

Tumor size greater than 4 cm increases relapse risk during active surveillance.
Rete testis invasion is independent risk factor for relapse warranting consideration of adjuvant therapy.
Lymphovascular invasion increases relapse risk influencing treatment decisions.
Patient compliance with surveillance schedule essential for safe active surveillance approach.
Geographic access to specialized testicular cancer surveillance facilities affects feasibility.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Stage I seminoma diagnosis after orchiectomy warrants discussion of active surveillance versus adjuvant options.
  • Specialized testicular cancer center referral with multidisciplinary expertise optimizes management.
  • New back pain, abdominal symptoms, weight loss during surveillance warrant urgent imaging evaluation.
  • Tumor marker elevation during surveillance requires immediate restaging and treatment planning.
  • Relapse during surveillance requires prompt salvage chemotherapy with EP or BEP regimens.

Treatment Methods

01
Active surveillance with serial tumor markers (beta-hCG, AFP, LDH) every 3 months for years 1-3, then less frequently.
02
Cross-sectional imaging with abdominopelvic CT or MRI at scheduled intervals tailored to relapse risk.
03
Clinical examination including testicular and inguinal lymph node assessment at surveillance visits.
04
Salvage chemotherapy with EP (etoposide, cisplatin) or BEP for relapsed disease provides excellent cure rates.
05
Comprehensive surveillance care with specialized testicular cancer center, patient education on relapse symptoms, fertility preservation counseling, contralateral testicular surveillance for second primary, smoking cessation, cardiovascular risk reduction, psychosocial support for surveillance anxiety, and survivorship care addressing treatment-free survivorship benefits provides optimal outcomes preserving cure with minimal treatment exposure for patients with stage I seminoma.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.